Table 4.
Literature review on other MGUS-related disorders.
| Author/Year | Patients number | MGUS type | Type of involvement | Type of therapy | Outcome | MGUS response |
|---|---|---|---|---|---|---|
| Milman 2015 (186) | 5 | IgG-κ, IgG-λ | Keratopathy | -Chemotherapy + keratoplasty (1) -BPM + keratoplasty (1) -Keratoplasty (1) -ASHC (1) -CVAF (1) |
-Stabilization (3 years) -Recurrence (4 years) -Stabilization (2 years) -Stabilization (7 years) -Recurrence after 1 month |
N/A |
| Branellec 2012 (187) | 4 | IgG-κ, IgA-λ, IgG-λ | Acquired C1 inhibitor deficiency | Rituximab (4) + C1 inhibitor concentrate (3) + tranexamic acid (1) + IV cyclophosphamide (1) + corticosteroids (1) | Complete (2), partial response (2) | N/A |
| Cicardi 2003 (188) | 23 | IgG-λ, IgG-κ, IgM-κ, IgM-λ, IgA-λ | Acquired C1 inhibitor deficiency | -antithrombotic (6) -antifibrinolytic (13) -C1 inhibitor concentrate (12) |
-Complete (2), no response (4) -Complete (8), partial (4), none (1) -Complete (9), partial response (3) |
N/A |
| Gobert 2016 (189) | 6 | IgM-κ, IgM-λ, IgA-κ, IgA-λ, IgG-κ, IgG-λ | Acquired C1 inhibitor deficiency | Rituximab (6) | Complete or partial response (5) | N/A |
| Bork 2019 (190) | 15 | IgG, IgM, IgA | Acquired C1 inhibitor deficiency | C1 inhibitor concentrate (15) (+icatibant/rituximab) | Complete response (14) | N/A |
| Frémeaux-Bacchi 2002 (191) | 12 | IgM-κ, IgM-λ, IgA-κ, IgA-λ, IgG κ | Acquired C1 inhibitor deficiency | -Danazol + antifibrinolytic/corticosteroid (12) -IV corticosteroids (2) -Chemotherapy (9) -IV Immunoglobulin (12) |
-N/A -Complete or partial response (2) -Complete or partial response (7) -No response (12) |
MM (1) |
| Voisin 2011 (192) | 14 | IgM-κ, IgM-λ, IgG-κ, IgG-λ | Acquired von Willebrand disease | -IVIG (8) -Desmopressin (5) -von Willebrand factor (2) |
-Complete response (2) -Complete response (3) -No response (2) |
N/A |
BPM, bortezomib + prednisone + melphalan; CVAF, corneal vascularization with amniotic membrane graft; MM, multiple myeloma; N/A, not available.